{"contentid": 487918, "importid": NaN, "name": "AstraZeneca to market Junshi\u00e2\u0080\u0099s toripalimab in China", "introduction": "Anglo-Swedish drugmaker AstraZeneca has been granted exclusive promotion rights for Junshi Biosciences\u00e2\u0080\u0099 toripalimab in mainland China for urothelial carcinoma and for all indications in non-core areas.", "content": "<p>Anglo-Swedish drugmaker AstraZeneca (LSE: AZN) has been granted exclusive promotion rights for Junshi Biosciences&rsquo; (HKEX: 1877) toripalimab in mainland China for urothelial carcinoma and for all indications in non-core areas.</p>\n<p>Toripalimab was the first domestic anti-PD-1 monoclonal antibody approved for marketing in China. Junshi will continue to be responsible for its promotion of other indications in core areas.</p>\n<p><span class=\"pullQuote\">\"This innovative drug with excellent performance in efficacy and safety will achieve greater success in the Chinese market\"</span>The two companies will continue to explore business collaborations in overseas markets including emerging markets.</p>\n<p>Ning Li, chief executive of Shanghai-based Junshi, said: &ldquo;We are confident that by leveraging the extensive networks AstraZeneca has established over the years, and especially by utilizing its ability to promote in the county-level markets, this innovative drug with excellent performance in efficacy and safety will achieve greater success in the Chinese market and will enable more patients to receive timely and effective treatment.</p>\n<p>&ldquo;Under the guidance of the company&rsquo;s &lsquo;In China, for global&rsquo; strategy, we also look forward to more in-depth collaborations with AstraZeneca in a wider range of fields in order to provide better and more affordable treatment options to patients in China and all over the world.&rdquo;</p>\n<p>Financial terms of the agreement were not disclosed.</p>", "date": "2021-03-02 12:56:00", "meta_title": NaN, "meta_keywords": NaN, "meta_description": NaN, "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-02 12:49:47", "updated": "2021-03-02 13:47:37", "access": NaN, "url": "https://www.thepharmaletter.com/article/astrazeneca-to-market-junshi-s-toripalimab-in-china", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "astrazeneca_china.jpg", "image2id": "astrazeneca_china_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Immuno-oncology, Oncology", "topic_tag": "Asia Pacific, Deals, Focus On, Licensing", "geography_tag": "China", "company_tag": "AstraZeneca, Junshi Biosciences", "drug_tag": "toripalimab", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-02 12:56:00"}